CRISPR Therapeutics general counsel James R. Kasinger disposes of common shares worth $626,459.6
CRSP•General counsel and secretary James R. Kasinger sold 10,400 CRISPR Therapeutics shares on Sept. 22 for $60.2365 each, after exercising options for the same number of shares at $13.62; his direct holdings fell to 94,784 shares.
1. Share sale and option exercise
James R. Kasinger, CRISPR Therapeutics’ general counsel and secretary, sold 10,400 common shares on Sept. 22 at $60.2365 per share. He exercised options for 10,400 shares at $13.62 each on the same day. His directly held common shares fell to 94,784 following the transactions.
